Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|August 5, 2026 (Updated: July 30, 2026)

The BioPharm Brief: Platforms, Precision, and Patient Access

Listen
0:00 / 0:00

Today’s BioPharm Brief highlights new advances in engineered tissues, regenerative medicine, and biologics delivery, including clinical progress for a tissue-engineered therapy, late-stage wound healing data, and a major subcutaneous delivery licensing deal.

<iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8936510/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we’re looking at three stories spanning regenerative medicine, wound healing, and drug delivery technologies.

First, Satellite Bio has received FDA clearance for its Investigational New Drug application for SB-101, marking the company’s transition into the clinical stage. The candidate is based on Satellite Bio’s tissue-engineered platform, which is designed to create implantable tissues intended to restore or replace biological functions. The company plans to evaluate SB-101 in a clinical study as it advances its approach to engineered tissue therapeutics.

Next, Applied Biological Laboratories has reported phase III data for BioXheal in diabetic foot ulcers, a chronic wound condition associated with significant morbidity and healthcare burden. The company’s late-stage program is focused on evaluating BioXheal as a potential treatment option to support wound healing in patients with diabetic foot ulcers.

And finally, Alteogen has expanded the reach of its Hybrozyme platform through a subcutaneous delivery licensing agreement valued at up to $365 million. The technology uses recombinant human hyaluronidase to enable subcutaneous administration of biologics that are traditionally delivered intravenously. The deal highlights continued industry interest in delivery technologies that could improve convenience and potentially reduce treatment burden for patients receiving biologic therapies.

From engineered tissues entering the clinic to next-generation delivery platforms reshaping how biologics are administered, these stories highlight how innovation continues beyond the molecule itself.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Satellite Bio’s SB-101 IND clearance moves engineered tissue technology into clinical development.
  • Applied Biologicals is advancing BioXheal through late-stage evaluation for diabetic foot ulcers.
  • Alteogen’s Hybrozyme platform reflects continued momentum around subcutaneous delivery approaches for biologics.

Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.